Search

Your search keyword '"Papadogiannis, Argiroula"' showing total 5 results
Start Over Author "Papadogiannis, Argiroula"
5 results on '"Papadogiannis, Argiroula"'

1. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma

Author

Kyrtsonis, Marie-Christine, Vassilakopoulos, Theodoros P., Kafasi, Nicoletta, Sachanas, Sotirios, Tzenou, Tatiana, Papadogiannis, Argiroula, Galanis, Zacharoula, Kalpadakis, Christina, Dimou, Maria, Kyriakou, Elias, Angelopoulou, Maria K., Dimopoulou, Maria N., Siakantaris, Marina P., Dimitriadou, Evangelia M., Kokoris, Styliani I., Panayiotidis, Panayiotis, and Pangalis, Gerassimos A.

Published
2007

2. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma

Author

Kyrtsonis, Marie-Christine Vassilakopoulos, Theodoros P. Kafasi, Nicoletta Sachanas, Sotirios Tzenou, Tatiana Papadogiannis, Argiroula Galanis, Zacharoula Kalpadakis, Christina Dimou, Maria Kyriakou, Elias Angelopoulou, Maria K. Dimopoulou, Maria N. Siakantaris, Marina P. Dimitriadou, Evangelia M. and Kokoris, Styliani I. Panayiotidis, Panayiotis Pangalis, Gerassimos A.

Abstract

The prognostic value of baseline serum free light chain ratio (sFLCR) was investigated in 94 multiple myeloma (MM) patients. sFLCR was calculated as kappa/lambda or lambda/kappa, depending on the patients’ dominating monoclonal light chain. Median baseline sFLCR was 3.57 in kappa-MM patients, 45.09 in lambda-MM. ‘High’ sFLCR (>= the observed median value for kappa- and lambda-MM respectively) correlated with elevated serum creatinine and lactate dehydrogenase, extensive marrow infiltration and light chain type MM. The 5-year disease-specific survival was 82% and 30% in patients with sFLCR lower than and equal or greater than the median, respectively (P = 0.0001). sFLCR was an independent prognostic factor.

Published
2007

3. Serum free light chain ratio (FLCR) at diagnosis constitute a powerful prognostic factor of survival in multiple myeloma (MM)

Author

Kyrtsonis, Marie-Christine Vassilakopoulos, Theodoros P. Kafasi, Nicoletta Sachanas, Sotirios Tzenou, Tatiana Papadogiannis, Argiroula Galanis, Zacharoula Kalpadakis, Christina Dimou, Maria Kyriakou, Elias Angelopoulou, Maria K. Dimopoulou, Maria N. Siakantaris, Marina P. Kokoris, Styliam I. and Dimitriadou, Evangelia M. Panayiotidis, Panayiotis Pangalis, Gerassimos A.

Published
2006

4. Serum Free Light Chain Ratio (FLCR) at Diagnosis Constitute a Powerful Prognostic Factor of Survival in Multiple Myeloma (MM).

Author

Kyrtsonis, Marie-Christine, primary, Vassilakopoulos, Theodoros P., additional, Kafasi, Nicoletta, additional, Sachanas, Sotirios, additional, Tzenou, Tatiana, additional, Papadogiannis, Argiroula, additional, Galanis, Zacharoula, additional, Kalpadakis, Christina, additional, Dimou, Maria, additional, Kyriakou, Elias, additional, Angelopoulou, Maria K., additional, Dimopoulou, Maria N., additional, Siakantaris, Marina P., additional, Kokoris, Styliani I., additional, Dimitriadou, Evangelia M., additional, Panayiotidis, Panayiotis, additional, and Pangalis, Gerassimos A., additional

Published
2006
Full Text
View/download PDF

5. Serum levels of soluble syndecan-1 in Hodgkin's lymphoma.

Author

Vassilakopoulos TP, Kyrtsonis MC, Papadogiannis A, Nadali G, Angelopoulou MK, Tzenou T, Dimopoulou MN, Siakantaris MP, Kontopidou FN, Kalpadakis C, Kokoris SI, Dimitriadou EM, Tsaftaridis P, Pizzolo G, and Pangalis GA

Subjects
Adolescent, Adult, Aged, Disease-Free Survival, Female, Hodgkin Disease pathology, Humans, Male, Middle Aged, Syndecan-1, Syndecans, Hodgkin Disease blood, Membrane Glycoproteins blood, Proteoglycans blood
Abstract

Background: Syndecan-1 (CD138) is expressed by the Hodgkin-Reed-Sternberg (HRS) cells of classic Hodgkin's lymphoma (cHL), but not in nodular lymphocyte-predominant HL. Syndecan-1 may be involved in the interaction between HRS cells and the cellular and stromal microenvironment typical of nodular sclerosing HL., Patients and Methods: Serum levels of soluble syndecan-1 were determined by ELISA in 66 patients with HL and 14 age- and sex-matched healthy individuals., Results: The levels of syndecan-1 were higher in HL patients than controls (100.2 +/- 35.9 ng/ml vs. 67.9 +/- 24.5 ng/ml, p < 0.001). They marginally correlated with advanced age (p = 0.06), male gender (p = 0.07) and consequently high IPS (p = 0.01), but did not correlate with markers of tumor burden and prognosis, including serum interleukin-10 and soluble CD30. At 6 years, failure-free survival was 70 +/- 9% vs. 50 +/- 11% (p = 0.32) for patients with serum soluble syndecan-1 levels above or below the observed median value of 91 ng/ml., Conclusion: The serum levels of syndecan-1 were elevated in patients with HL, but were not strongly correlated with other potential prognostic factors. Their effect on prognosis deserves further evaluation.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results